Global Amyotrophic Lateral Sclerosis Treatment Market 2019-2023
SKU ID : TNV-13792997 | Publishing Date : 28-Dec-2018 | No. of pages : 103
Detailed TOC of Global Amyotrophic Lateral Sclerosis Treatment Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
• Pipeline analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Intravenous - Market size and forecast 2018-2023
• Oral - Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas - Market size and forecast 2018-2023
• EMEA - Market size and forecast 2018-2023
• APAC - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Market trends
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• ITALFARMACO
• Mitsubishi Tanabe Pharma
• Sanofi
PART 14: APPENDIX
• Research methodology
• List of abbreviations
Exhibit 01: Global central nervous system (CNS) disorders drugs market
Exhibit 02: Segments of global central nervous system (CNS) disorders drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Late-stage pipeline drugs for ALS
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Intravenous - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Intravenous - Year-over-year growth 2019-2023 (%)
Exhibit 22: Oral - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Oral - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 30: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 32: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 34: Key leading countries
Exhibit 35: Market opportunity
Exhibit 36: Pipeline drugs for ALS
Exhibit 37: Impact of drivers and challenges
Exhibit 38: Vendor landscape
Exhibit 39: Landscape disruption
Exhibit 40: Vendors covered
Exhibit 41: Vendor classification
Exhibit 42: Market positioning of vendors
Exhibit 43: ITALFARMACO - Vendor overview
Exhibit 44: ITALFARMACO - Organizational developments
Exhibit 45: ITALFARMACO - Key offerings
Exhibit 46: Mitsubishi Tanabe Pharma - Vendor overview
Exhibit 47: Mitsubishi Tanabe Pharma - Business segments
Exhibit 48: Mitsubishi Tanabe Pharma - Organizational developments
Exhibit 49: Mitsubishi Tanabe Pharma - Geographic focus
Exhibit 50: Mitsubishi Tanabe Pharma - Key offerings
Exhibit 51: Sanofi - Vendor overview
Exhibit 52: Sanofi - Business segments
Exhibit 53: Sanofi - Organizational developments
Exhibit 54: Sanofi - Geographic focus
Exhibit 55: Sanofi - Segment focus
Exhibit 56: Sanofi - Key offerings
Exhibit 57: Validation techniques employed for market sizing
Keyplayers in Global Amyotrophic Lateral Sclerosis Treatment Market 2019-2023
ITALFARMACOMitsubishi Tanabe Pharma
Sanofi